Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1952 2
1960 2
1961 3
1962 4
1963 6
1964 2
1966 1
1967 3
1968 1
1969 3
1970 4
1971 3
1972 2
1973 2
1974 6
1975 4
1976 6
1977 11
1978 3
1979 10
1980 9
1981 3
1982 8
1983 11
1984 12
1985 7
1986 6
1987 17
1988 14
1989 17
1990 32
1991 23
1992 24
1993 20
1994 15
1995 24
1996 19
1997 25
1998 17
1999 27
2000 29
2001 28
2002 25
2003 55
2004 57
2005 80
2006 81
2007 66
2008 72
2009 94
2010 104
2011 138
2012 111
2013 102
2014 109
2015 132
2016 153
2017 129
2018 141
2019 168
2020 180
2021 210
2022 260
2023 196
2024 169
2025 1

Text availability

Article attribute

Article type

Publication date

Search Results

2,979 results

Results by year

Filters applied: . Clear all
Page 1
Single-cell RNA sequencing and spatial transcriptomics reveal cancer-associated fibroblasts in glioblastoma with protumoral effects.
Jain S, Rick JW, Joshi RS, Beniwal A, Spatz J, Gill S, Chang AC, Choudhary N, Nguyen AT, Sudhir S, Chalif EJ, Chen JS, Chandra A, Haddad AF, Wadhwa H, Shah SS, Choi S, Hayes JL, Wang L, Yagnik G, Costello JF, Diaz A, Heiland DH, Aghi MK. Jain S, et al. Among authors: chen js. J Clin Invest. 2023 Mar 1;133(5):e147087. doi: 10.1172/JCI147087. J Clin Invest. 2023. PMID: 36856115 Free PMC article.
A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, Bell ML, Blore JD, Blyth F, Bonner C, Borges G, Bourne R, Boussinesq M, Brauer M, Brooks P, Bruce NG, Brunekreef B, Bryan-Hancock C, Bucello C, Buchbinder R, Bull F, Burnett RT, Byers TE, Calabria B, Carapetis J, Carnahan E, Chafe Z, Charlson F, Chen H, Chen JS, Cheng AT, Child JC, Cohen A, Colson KE, Cowie BC, Darby S, Darling S, Davis A, Degenhardt L, Dentener F, Des Jarlais DC, Devries K, Dherani M, Ding EL, Dorsey ER, Driscoll T, Edmond K, Ali SE, Engell RE, Erwin PJ, Fahimi S, Falder G, Farzadfar F, Ferrari A, Finucane MM, Flaxman S, Fowkes FG, Freedman G, Freeman MK, Gakidou E, Ghosh S, Giovannucci E, Gmel G, Graham K, Grainger R, Grant B, Gunnell D, Gutierrez HR, Hall W, Hoek HW, Hogan A, Hosgood HD 3rd, Hoy D, Hu H, Hubbell BJ, Hutchings SJ, Ibeanusi SE, Jacklyn GL, Jasrasaria R, Jonas JB, Kan H, Kanis JA, Kassebaum N, Kawakami N, Khang YH, Khatibzadeh S, Khoo JP, Kok C, Laden F, Lalloo R, Lan Q, Lathlean T, Leasher JL, Leigh J, Li Y, Lin JK, Lipshultz SE, London S, Lozano R… See abstract for full author list ➔ Lim SS, et al. Among authors: chen js. Lancet. 2012 Dec 15;380(9859):2224-60. doi: 10.1016/S0140-6736(12)61766-8. Lancet. 2012. PMID: 23245609 Free PMC article.
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, Kitano M, Lee CK, Kim JW, Chen MH, Suksombooncharoen T, Ikeda M, Lee MA, Chen JS, Potemski P, Burris HA 3rd, Ostwal V, Tanasanvimon S, Morizane C, Zaucha RE, McNamara MG, Avallone A, Cundom JE, Breder V, Tan B, Shimizu S, Tougeron D, Evesque L, Petrova M, Zhen DB, Gillmore R, Gupta VG, Dayyani F, Park JO, Buchschacher GL Jr, Rey F, Kim H, Wang J, Morgan C, Rokutanda N, Żotkiewicz M, Vogel A, Valle JW. Oh DY, et al. Among authors: chen js. Lancet Gastroenterol Hepatol. 2024 Aug;9(8):694-704. doi: 10.1016/S2468-1253(24)00095-5. Epub 2024 May 29. Lancet Gastroenterol Hepatol. 2024. PMID: 38823398 Clinical Trial.
Compartment Syndrome of the Foot.
Chen JS, Tejwani NC. Chen JS, et al. Orthop Clin North Am. 2022 Jan;53(1):83-93. doi: 10.1016/j.ocl.2021.08.005. Epub 2021 Oct 28. Orthop Clin North Am. 2022. PMID: 34799026 Review.
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M. Ueno H, et al. Among authors: chen js. J Clin Oncol. 2013 May 1;31(13):1640-8. doi: 10.1200/JCO.2012.43.3680. Epub 2013 Apr 1. J Clin Oncol. 2013. PMID: 23547081 Clinical Trial.
Total Synthesis of Kibdelomycin.
He C, Wang Y, Bi C, Peters DS, Gallagher TJ, Teske J, Chen JS, Corsetti R, D'Onofrio A, Lewis K, Baran PS. He C, et al. Among authors: chen js. Angew Chem Int Ed Engl. 2022 Aug 8;61(32):e202206183. doi: 10.1002/anie.202206183. Epub 2022 Jul 6. Angew Chem Int Ed Engl. 2022. PMID: 35704446 Free PMC article.
SPARC: a potential target for functional nanomaterials and drugs.
Jiang S, Sun HF, Li S, Zhang N, Chen JS, Liu JX. Jiang S, et al. Among authors: chen js. Front Mol Biosci. 2023 Jul 28;10:1235428. doi: 10.3389/fmolb.2023.1235428. eCollection 2023. Front Mol Biosci. 2023. PMID: 37577749 Free PMC article. Review.
2,979 results